Screener
Regeneron Pharmaceuticals REGN Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's return on invested capital?
- Regeneron Pharmaceuticals (REGN) reported return on invested capital of 10.3% in Q2 2026.
- How has Regeneron Pharmaceuticals's return on invested capital changed year-over-year?
- Regeneron Pharmaceuticals's return on invested capital decreased by 12.7% year-over-year, from 11.8% to 10.3%.
- What is the long-term trend for Regeneron Pharmaceuticals's return on invested capital?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's return on invested capital has grown at a -19.7% compound annual growth rate (CAGR), from 30.4% to 10.1%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.
Ask your AI about Regeneron Pharmaceuticals's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude